Taking two or more different drugs together may result in an alteration in the effectiveness or in the side-effects of one or more of the drugs. Pharmacokinetics (PK) is the study of how a drug is absorbed into the body and distributed in different parts of the body. Pharmacodynamics (PD) is the study of the impact of different concentrations of a drug on the body.

Drug interactions and pharmacokinetics: latest news

Drug interactions and pharmacokinetics resources

Drug interactions and pharmacokinetics features

Drug interactions and pharmacokinetics news from aidsmap

More news

Drug interactions and pharmacokinetics news selected from other sources

  • TB CAB statement on safety of using bedaquiline and delamanid together

    he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

    14 March 2019 | TB Online
  • Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

    Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.

    12 March 2019 | HIV i-Base
  • Weight Monitoring Key to Pediatric ART Dosing in Resource-Limited Countries

    Study findings in a short communication published in HIV Medicine revealed that a large percentage of children living with HIV were prescribed inappropriate doses of antiretroviral therapy (ART) at a pediatric outpatient clinic at Harare Central Hospital in Zimbabwe.

    27 February 2019 | Infectious Disease Advisor
  • Many people take drugs that interfere with their blood pressure pills

    People who take pills to lower their blood pressure often take other drugs that reduce the pills’ effectiveness, a recent study suggests.

    22 August 2018 | Reuters
  • Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

    New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.

    18 July 2018 | MHRA
  • Closer Monitoring Recommended for Older Patients Treated With Dolutegravir for HIV

    The maximum concentration of the integrase inhibitor dolutegravir (DTG) was significantly higher in people living with HIV who are more than 60 years old compared with younger individuals, according to new findings published in Clinical Infectious Diseases.There have been recent concerns about DTG-related neuropsychiatric toxicity, especially among older patients with HIV.

    11 June 2018 | Infectious Disease Advisor
  • FDA says Prezcobix should not be given to pregnant women

    Darunavir/cobicistat — marketed as Prezcobix (Janssen) in the United States — should not be given to pregnant women with HIV because of substantially lower exposures of the two medications during pregnancy, the FDA said. The agency updated the label for the once-daily, fixed-dose tablet to reflect the change, which it said was based on data from a small clinical trial involving pregnant women.

    11 June 2018 | Healio (requires free registration)
  • Differing drug distribution in penis and rectum of men taking TDF/FTC PrEP

    Men using tenofovir/emtricitabine (TDF/FTC) for preexposure prophylaxis (PrEP) had detectable drug levels in the urethra more often than on the glans penis, according to results of an 18-man study. FTC concentrations proved similar on urethral and rectal swabs, but tenofovir (TFV) levels were lower on urethral specimens than on rectal swabs.

    25 May 2018 | NATAP
  • How Well Do Docs Manage Potential Conflicts Between Hep C and HIV Meds?

    A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

    10 April 2018 | Poz
  • Dolutegravir and Rifapentine study stopped due to serious toxicities

    A study examining pharmacokinetic interactions between the first-line HIV drug dolutegravir and a once-weekly tuberculosis regimen was terminated early after NIH researchers found that the combined use of the treatments led to “unexpected and serious toxicities” in healthy participants.

    01 March 2018 | Medical Brief
More news
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.